Join us at the AMM conference in Boston, MA. The Alliance for mRNA Medicines (AMM) brings together senior executives and top decision-makers in the mRNA industry to advance pioneering research into ...
Why Attend SITC 2024? SITC 2024 provides a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy. ...
Immunomic Therapeutics Reports Positive Results from Its Phase 1 Clinical Trial of ITI-3000 in Patients Diagnosed with Merkel Cell Carcinoma ITI-3000 Demonstrated a Favorable Safety and Tolerability Profile Patients showed ...
Immunomic Therapeutics' article titled, "LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition," has been published in Frontiers ...
Immunomic Therapeutics Doses First Patient in its Phase 1 Clinical Trial of ITI-1001, a pDNA Vaccine for the Treatment of Glioblastoma Multiforme -Top-Line Data Expected in the Second Quarter of ...
July 14, 2023 Immunomic Therapeutics is highlighted in Washington Business Journal's cover story, “Life sciences funding is tough, but there are still avenues to money.” WBJ talks about how a ...
Please take a look at our very own scientists and executives that were highlighted in BioHive, an online community platform for the Bio health Industry.
ASTELLAS Announces FDA Fast Track Designation for ASP0892 DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions Due to Peanut Allergy NEWS PROVIDED BY Astellas Pharma Inc. Dec 20, 2016, 08:00 ...
February 02, 2017 06:45 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced the finalists for their Cancer Discovery Incubator Award: Alcamena ...